Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ZHENYA TANG and L JEFFREY MEDEIROS.
ZHENYA TANG
Connection Strength
10.433
L JEFFREY MEDEIROS
  1. Correction: Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis. Mod Pathol. 2020 Oct; 33(10):2088.
    View in: PubMed
    Score: 0.750
  2. Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes. Cancers (Basel). 2020 Jul 14; 12(7).
    View in: PubMed
    Score: 0.739
  3. Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis. Mod Pathol. 2020 10; 33(10):2035-2045.
    View in: PubMed
    Score: 0.730
  4. Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects. Int J Mol Sci. 2019 Aug 13; 20(16).
    View in: PubMed
    Score: 0.693
  5. Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. Cancer Genet. 2019 04; 233-234:21-31.
    View in: PubMed
    Score: 0.673
  6. Reply to Lambros et al. Mod Pathol. 2018 03; 31(3):541-542.
    View in: PubMed
    Score: 0.627
  7. Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. Mod Pathol. 2018 02; 31(2):307-312.
    View in: PubMed
    Score: 0.607
  8. Optical Genome Mapping Helps to Identify BCR::JAK2 Rearrangement Arising from Cryptic Complex Chromosomal Aberrations: A Case Report and Literature Review. Genes (Basel). 2023 12 08; 14(12).
    View in: PubMed
    Score: 0.234
  9. Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells. Cancers (Basel). 2023 Dec 02; 15(23).
    View in: PubMed
    Score: 0.233
  10. 3q26.2/MECOM Rearrangements by Pericentric Inv(3): Diagnostic Challenges and Clinicopathologic Features. Cancers (Basel). 2023 Jan 11; 15(2).
    View in: PubMed
    Score: 0.220
  11. Classic Hodgkin lymphoma with marked granulomatous reaction: A clinicopathologic study of 20 cases. Hum Pathol. 2023 04; 134:114-123.
    View in: PubMed
    Score: 0.219
  12. Clinical impact of 5'MYC or 3'MYC gain/loss detected by FISH in patients with aggressive B-cell lymphomas. Cancer Genet. 2023 04; 272-273:1-8.
    View in: PubMed
    Score: 0.219
  13. PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia. Genes (Basel). 2022 07 29; 13(8).
    View in: PubMed
    Score: 0.213
  14. 3'CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant. Ann Hematol. 2022 Apr; 101(4):847-854.
    View in: PubMed
    Score: 0.206
  15. Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies. Cancer Genet. 2022 04; 262-263:23-29.
    View in: PubMed
    Score: 0.204
  16. Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia. Leuk Res. 2021 09; 108:106616.
    View in: PubMed
    Score: 0.196
  17. Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leuk Lymphoma. 2020 12; 61(13):3243-3246.
    View in: PubMed
    Score: 0.185
  18. t(3;8)(q26.2;q24) Often Leads to MECOM/MYC Rearrangement and Is Commonly Associated with Therapy-Related Myeloid Neoplasms and/or Disease Progression. J Mol Diagn. 2019 03; 21(2):343-351.
    View in: PubMed
    Score: 0.166
  19. Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. Leuk Res. 2018 10; 73:86-94.
    View in: PubMed
    Score: 0.163
  20. Sex chromosome loss after allogeneic hematopoietic stem cell transplant in patients with hematologic neoplasms: a diagnostic dilemma for clinical cytogeneticists. Mol Cytogenet. 2016; 9:62.
    View in: PubMed
    Score: 0.141
  21. Clinical significance of acquired loss of the X chromosome in bone marrow. Leuk Res. 2016 08; 47:109-13.
    View in: PubMed
    Score: 0.139
  22. Simultaneous deletion of 3'ETV6 and 5'EWSR1 genes in blastic plasmacytoid dendritic cell neoplasm: case report and literature review. Mol Cytogenet. 2016; 9:23.
    View in: PubMed
    Score: 0.136
  23. Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement. Am J Clin Pathol. 2024 Nov 04; 162(5):455-463.
    View in: PubMed
    Score: 0.062
  24. The spectrum of hematologic neoplasms in patients with Li-Fraumeni syndrome. Am J Hematol. 2024 Dec; 99(12):2416-2419.
    View in: PubMed
    Score: 0.062
  25. Morphology, immunophenotype, and suggested diagnostic criteria of TCL1 family-negative T-prolymphocytic leukemia. Am J Clin Pathol. 2024 Jun 30.
    View in: PubMed
    Score: 0.061
  26. Myeloid neoplasm with <10% blasts and t(3;5)(q25.1;q34)/NPM::MLF1: A classification dilemma. Am J Hematol. 2024 Sep; 99(9):1827-1829.
    View in: PubMed
    Score: 0.059
  27. Recurrent Somatic Copy Number Alterations and Their Association with Oncogene Expression Levels in High-Grade Ovarian Serous Carcinoma. Life (Basel). 2023 Nov 10; 13(11).
    View in: PubMed
    Score: 0.058
  28. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in?situ hybridization. Cancer Cytopathol. 2024 Jan; 132(1):41-49.
    View in: PubMed
    Score: 0.058
  29. T-prolymphocytic leukemia: TCL1 or MTCP1 rearrangement is not mandatory to establish diagnosis. Leukemia. 2023 09; 37(9):1919-1921.
    View in: PubMed
    Score: 0.057
  30. DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma. Haematologica. 2023 06 01; 108(6):1604-1615.
    View in: PubMed
    Score: 0.056
  31. Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis. Cancer Med. 2023 07; 12(13):14293-14304.
    View in: PubMed
    Score: 0.056
  32. DDX41 mutations in patients with non-myeloid hematologic neoplasms. Am J Hematol. 2023 08; 98(8):E193-E196.
    View in: PubMed
    Score: 0.056
  33. T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases. Am J Clin Pathol. 2023 04 04; 159(4):325-336.
    View in: PubMed
    Score: 0.056
  34. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma?variant. Virchows Arch. 2023 Jun; 482(6):1011-1019.
    View in: PubMed
    Score: 0.055
  35. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology. 2023 Jun; 55(4):514-524.
    View in: PubMed
    Score: 0.055
  36. Flow cytometry immunophenotypic features of pure erythroid leukemia and the distinction from reactive erythroid precursors. Cytometry B Clin Cytom. 2022 11; 102(6):440-447.
    View in: PubMed
    Score: 0.054
  37. B-lymphoblastic leukemia with Burkitt-like morphology and aberrant myeloperoxidase expression: A diagnostic conundrum. EJHaem. 2022 Nov; 3(4):1406-1408.
    View in: PubMed
    Score: 0.054
  38. Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases. Haematologica. 2022 09 01; 107(9):2232-2237.
    View in: PubMed
    Score: 0.054
  39. Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel). 2022 Jul 11; 14(14).
    View in: PubMed
    Score: 0.053
  40. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022 07 07; 140(1):58-72.
    View in: PubMed
    Score: 0.053
  41. Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. Pathology. 2022 Dec; 54(7):893-899.
    View in: PubMed
    Score: 0.053
  42. Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry. Cytometry B Clin Cytom. 2022 07; 102(4):283-291.
    View in: PubMed
    Score: 0.053
  43. Myeloid neoplasms with 8q24/MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survival. Br J Haematol. 2022 08; 198(3):604-608.
    View in: PubMed
    Score: 0.053
  44. MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome. Cancers (Basel). 2022 May 14; 14(10).
    View in: PubMed
    Score: 0.052
  45. Primary mediastinal germ cell tumor and clonally related and unique hematologic neoplasms with i(12p) and TP53 mutation: A report of two cases. Ann Diagn Pathol. 2022 Aug; 59:151951.
    View in: PubMed
    Score: 0.052
  46. From the archives of MD Anderson Cancer Center: Intravascular large B-cell lymphoma with numerous circulating lymphoma cells. Ann Diagn Pathol. 2022 Jun; 58:151934.
    View in: PubMed
    Score: 0.052
  47. CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. Cancers (Basel). 2021 Oct 26; 13(21).
    View in: PubMed
    Score: 0.050
  48. Clonal cytogenetic abnormalities in donor-derived cells after sex mismatched allogeneic stem cell transplantation. Cancer Genet. 2021 11; 258-259:120-130.
    View in: PubMed
    Score: 0.050
  49. MET Amplification (MET/CEP7 Ratio?= 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non-Small-cell Lung Cancer. Clin Lung Cancer. 2021 07; 22(4):e512-e518.
    View in: PubMed
    Score: 0.047
  50. Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcome. Exp Mol Pathol. 2021 02; 118:104572.
    View in: PubMed
    Score: 0.047
  51. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol. 2021 05; 129(5):374-382.
    View in: PubMed
    Score: 0.047
  52. Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. Mod Pathol. 2021 02; 34(2):300-313.
    View in: PubMed
    Score: 0.047
  53. From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later. Ann Diagn Pathol. 2021 Feb; 50:151649.
    View in: PubMed
    Score: 0.047
  54. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J. 2020 08 26; 10(8):86.
    View in: PubMed
    Score: 0.047
  55. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. Ann Hematol. 2020 Oct; 99(10):2343-2349.
    View in: PubMed
    Score: 0.047
  56. Chronic myeloid leukemia presenting in lymphoblastic crisis, a differential diagnosis with Philadelphia-positive B-lymphoblastic leukemia. Leuk Lymphoma. 2020 12; 61(12):2831-2838.
    View in: PubMed
    Score: 0.046
  57. T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid. Leukemia. 2020 09; 34(9):2509-2512.
    View in: PubMed
    Score: 0.045
  58. iAMP21 in acute myeloid leukemia is associated with complex karyotype, TP53 mutation and dismal outcome. Mod Pathol. 2020 07; 33(7):1389-1397.
    View in: PubMed
    Score: 0.045
  59. Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors. Cancer Genet. 2020 02; 241:57-60.
    View in: PubMed
    Score: 0.044
  60. Homogeneously staining region (hsr) on chromosome 11 is highly specific for KMT2A amplification in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Cancer Genet. 2019 10; 238:18-22.
    View in: PubMed
    Score: 0.043
  61. Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens. Leuk Res. 2019 09; 84:106176.
    View in: PubMed
    Score: 0.043
  62. Is hyperdiploidy a favorable cytogenetics in adults with B-lymphoblastic leukemia? Cancer Med. 2019 08; 8(9):4093-4099.
    View in: PubMed
    Score: 0.043
  63. PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel). 2019 May 19; 11(5).
    View in: PubMed
    Score: 0.043
  64. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019 07; 94(7):757-766.
    View in: PubMed
    Score: 0.043
  65. Characterization of chronic myelomonocytic leukemia with TP53 mutations. Leuk Res. 2018 07; 70:97-99.
    View in: PubMed
    Score: 0.040
  66. MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer. Oncotarget. 2018 Feb 27; 9(16):12959-12970.
    View in: PubMed
    Score: 0.039
  67. 8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. Leuk Res. 2018 03; 66:73-78.
    View in: PubMed
    Score: 0.039
  68. Bone marrow findings in blast phase of polycythemia vera. Ann Hematol. 2018 Mar; 97(3):425-434.
    View in: PubMed
    Score: 0.039
  69. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. Leuk Res. 2018 02; 65:25-28.
    View in: PubMed
    Score: 0.039
  70. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. Eur J Haematol. 2017 Dec; 99(6):536-543.
    View in: PubMed
    Score: 0.038
  71. Erratum to: Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol. 2017 07; 96(7):1239.
    View in: PubMed
    Score: 0.037
  72. Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera. Haematologica. 2017 09; 102(9):1511-1518.
    View in: PubMed
    Score: 0.037
  73. Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. Am J Hematol. 2017 May; 92(5):441-447.
    View in: PubMed
    Score: 0.037
  74. Clinical significance of isolated del(7p) in myeloid neoplasms. Leuk Res. 2017 04; 55:18-22.
    View in: PubMed
    Score: 0.036
  75. Role of complexity of variant Philadelphia chromosome in chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol. 2017 03; 96(3):501-504.
    View in: PubMed
    Score: 0.036
  76. Newly emerged isolated Del(7q) in patients with prior cytotoxic therapies may not always be associated with therapy-related myeloid neoplasms. Mod Pathol. 2016 07; 29(7):727-34.
    View in: PubMed
    Score: 0.034
  77. The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia. Mod Pathol. 2016 05; 29(5):444-51.
    View in: PubMed
    Score: 0.034
  78. Constitutional pericentric inversion of chromosome 9 has no impact on survival in chronic myelogenous leukemia. Ann Hematol. 2016 Mar; 95(4):657-9.
    View in: PubMed
    Score: 0.034
  79. Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression. Mol Cytogenet. 2015; 8:68.
    View in: PubMed
    Score: 0.033
  80. Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia. Am J Hematol. 2015 Oct; 90(10):882-7.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.